Mucin and bacterial biofilm matrix

The mucin and bacterial biofilm matrix is a complex, heterogeneous structural barrier composed of host-derived mucin glycoproteins and microbially-produced extracellular polymeric substances (EPS) [1, 3]. These EPS components typically include polysaccharides, proteins, and extracellular DNA (eDNA) that provide a scaffold for bacterial communities to thrive [3]. In chronic infections, such as those found in cystic fibrosis or chronic wounds, bacteria utilize this matrix to evade the host immune system and resist antibiotic penetration [1]. The interaction between host mucins and bacterial products increases the viscoelasticity of the environment, impairing natural clearance mechanisms like mucociliary transport [2]. Therapeutic targeting of this matrix involves the use of mucolytics to break disulfide bonds and nucleases to degrade eDNA, thereby thinning the matrix and facilitating clearance [2, 4]. Emerging treatments also focus on glycoside hydrolases that specifically target the bacterial exopolysaccharides within the biofilm to destabilize the structure [3]. By disrupting this physical barrier, these therapies aim to restore the efficacy of conventional antibiotics and improve patient outcomes in chronic inflammatory and infectious diseases [1, 2].

Other names

Mucus-biofilm complexBiofilm-mucus barrierExtracellular polymeric substances and mucin scaffoldInfected mucus matrix

Disruption of disulfide bonds in mucin glycoproteins, enzymatic degradation of extracellular DNA (eDNA), and hydrolysis of bacterial exopolysaccharides to reduce matrix viscosity and enhance antibiotic penetration [2, 3].